Biodexa Pharmaceuticals Plc: Business Overview, Financials & Competitive Analysis
Biodexa Pharmaceuticals Plc scores 4/10 on the AskCyborg Cyborg Score (Challenged). Early-stage rare-disease focused biotech with platform-enabled pipeline, but trading at distressed valuation with near-term capital and execution risks. Biodexa faces significant operational challenges evidenced by micro-cap valuation, recent share capital restructuring discussions (July 2026), regulatory halts, and shareholder rejections of key proposals (June 2026). While it possesses differentiated drug.
What is Biodexa Pharmaceuticals Plc's industry? Biodexa Pharmaceuticals Plc (biodexapharma.com) operates in Oncology Drugs. AskCyborg classifies Biodexa Pharmaceuticals Plc under Oncology Drugs in its company registry.
Biodexa Pharmaceuticals Plc is a clinical-stage biopharmaceutical company developing a pipeline of products for the treatment of diseases with unmet medical needs. The company's lead development programme, eRapa, is b...
Cyborg Score thesis
Early-stage rare-disease focused biotech with platform-enabled pipeline, but trading at distressed valuation with near-term...
Read the full analyst-debate transcript →Get the Latest Biodexa Pharmaceuticals Plc Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeBiodexa Pharmaceuticals Plc Overview
Pro stress-test →Biodexa Pharmaceuticals Plc is a clinical-stage biopharmaceutical company developing a pipeline of products for the treatment of diseases with unmet medical needs. The company's lead development programme, eRapa, is being readied for a phase 3 registration study in familial adenomatous polyposis (FAP), a rare and serious condition where the only successful treatment option is bowel resection.
Strategic Profile
Pro stress-test →The company's pipeline includes tolimidone under development for type 1 diabetes, and MTX110 being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months.
Competitive Landscape
Pro stress-test →Biodexa competes in oncology and rare disease biotech against larger established companies with broader pipelines. Primary competitors include sponsors of mTOR inhibitors (Novartis, Pfizer) in oncology, and type 1 diabetes developers (Eli Lilly, Novo Nordisk). In rare brain cancers and drug delivery, Biodexa's Q-Sphera and MidaCore platforms differentiate against generic competitors, though it lacks the scale and resources of major pharma.
Industry Context
Biodexa Pharmaceuticals Plc operates in Oncology Drugs.
Key facts
Founded: Unknown; incorporated as UK-listed biotech · Headquarters: Halesowen, United Kingdom · Employees: Unknown · Revenue: Pre-revenue (clinical stage); estimated operating burn approximately $5-10M annually based on typical Stage biotech profiles · Market cap: Approximately $1.6M (as of July 27, 2026)